Invivyd, Inc. (NASDAQ:IVVD) Short Interest Up 5.2% in January

Invivyd, Inc. (NASDAQ:IVVD) was the recipient of a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 6,620,000 shares, an increase of 5.2% from the January 15th total of 6,290,000 shares. Based on an average trading volume of 12,710,000 shares, the short-interest ratio is presently 0.5 days. Approximately 8.8% of the shares of the company are sold short.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on IVVD shares. Morgan Stanley cut their target price on Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a research note on Wednesday, November 20th. D. Boral Capital reissued a “buy” rating and set a $9.00 target price on shares of Invivyd in a research note on Monday, February 3rd. EF Hutton Acquisition Co. I raised Invivyd to a “strong-buy” rating in a research note on Wednesday, October 30th. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Invivyd in a research note on Tuesday, February 4th. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $7.89.

Insider Buying and Selling at Invivyd

In other Invivyd news, Director Terrance Mcguire sold 160,400 shares of the company’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $0.59, for a total transaction of $94,636.00. Following the completion of the sale, the director now directly owns 4,202,679 shares of the company’s stock, valued at $2,479,580.61. This represents a 3.68 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold a total of 816,466 shares of company stock valued at $423,214 in the last ninety days. Insiders own 17.90% of the company’s stock.

Institutional Investors Weigh In On Invivyd

Large investors have recently bought and sold shares of the stock. Proficio Capital Partners LLC acquired a new stake in Invivyd during the 3rd quarter valued at $27,000. Jane Street Group LLC boosted its holdings in shares of Invivyd by 290.5% during the fourth quarter. Jane Street Group LLC now owns 117,432 shares of the company’s stock worth $52,000 after purchasing an additional 87,358 shares during the last quarter. Barclays PLC boosted its holdings in shares of Invivyd by 7.8% during the fourth quarter. Barclays PLC now owns 127,180 shares of the company’s stock worth $56,000 after purchasing an additional 9,207 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in shares of Invivyd during the fourth quarter worth $74,000. Finally, JPMorgan Chase & Co. boosted its holdings in Invivyd by 644.1% in the fourth quarter. JPMorgan Chase & Co. now owns 256,900 shares of the company’s stock valued at $114,000 after acquiring an additional 222,375 shares during the last quarter. Institutional investors and hedge funds own 70.36% of the company’s stock.

Invivyd Price Performance

NASDAQ IVVD opened at $1.46 on Wednesday. Invivyd has a 1-year low of $0.35 and a 1-year high of $4.74. The company has a market capitalization of $174.65 million, a P/E ratio of -0.74 and a beta of 0.61. The business has a 50 day moving average price of $0.73 and a 200 day moving average price of $0.86.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.